Treatment of Acute Lymphoblastic Leukemia
- 12 January 2006
- journal article
- review article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 354 (2), 166-178
- https://doi.org/10.1056/nejmra052603
Abstract
Although the overall cure rate of acute lymphoblastic leukemia (ALL) in children is about 80 percent, affected adults fare less well. This review considers recent advances in the treatment of ALL, emphasizing issues that need to be addressed if treatment outcome is to improve further.Keywords
This publication has 100 references indexed in Scilit:
- Karyotypic abnormalities create discordance of germline genotype and cancer cell phenotypesNature Genetics, 2005
- Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cellsBlood, 2005
- MicroRNA expression profiles classify human cancersNature, 2005
- Infant acute lymphoblastic leukemia with MLL gene rearrangements: outcome following intensive chemotherapy and hematopoietic stem cell transplantationBlood, 2004
- Targeted cancer therapyNature, 2004
- Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic LeukemiaScience, 2004
- Overriding Imatinib Resistance with a Novel ABL Kinase InhibitorScience, 2004
- Epigenetics in human disease and prospects for epigenetic therapyNature, 2004
- Prediction of immunophenotype, treatment response, and relapse in childhood acute lymphoblastic leukemia using DNA microarraysLeukemia, 2004
- Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) Acute Lymphoblastic Leukemia Studies, 1982–1995Leukemia, 2000